Drug monitoring tool
Embodiments of the present disclosure relate to a drug monitoring tool. The drug monitoring tool comprises a data receiver and an interactive user interface. The data receiver is configured to receive a pharmacokinetic (PK) profile of a patient. The interactive user interface is configured to display, to the patient, a time-varying therapeutic plasma protein level of the patient. The time-varying therapeutic plasma protein level is based on an administered dose of a clotting factor VIII and the PK profile of the patient.
1. A drug monitoring tool, the tool comprising:
a data receiver configured to receive, from a secured server, a patient pharmacokinetic (PK) profile of a patient, wherein the secured server comprises: (I) a Bayesian model of pharmacokinetic (PK) profiles of sampled patients, the Bayesian model including (i) a therapeutic plasma protein clearance and (ii) a volume of distribution relationship for a therapeutic plasma protein based upon at least one of patient age or body weight, and (II) a PK server configured to determine the patient PK profile based upon the Bayesian model, and at least one of a bodyweight, von Willebrand factor level, and an age of the patient; and
an interactive user interface configured to:
display to the patient a graphical representation predictive of a time-varying therapeutic plasma protein level of the patient, the time-varying therapeutic plasma protein level determined by the drug monitoring tool based on the timing and amount of an administered dose of a clotting factor VIII to the patient and the patient PK profile; and
delineate a plurality of zones within the graphical representation associated with the time-varying therapeutic plasma protein level, the plurality of zones comprising at least:
a safe zone indicating to the patient that the time-varying therapeutic plasma protein level is within a first concentration range considered safe for physical activity; and
a danger zone indicating to the patient that the time-varying therapeutic plasma protein level is within a second concentration range and physical activity should be limited.
2. The drug monitoring tool of claim 1 , wherein:
the data receiver is a camera configured to scan a quick response (QR) code storing patient information that includes at least PK profile information; and
the drug monitoring tool further comprising a QR code processor configured to extract and process the patient PK profile.
3. The drug monitoring tool of claim 2 , further comprising a QR code generator configured to generate the QR code having patient information encrypted using AES-256 encryption with cipher block chaining (CBC) and public-key cryptography standards (PKCS) padding.
4. The drug monitoring tool of claim 3 , wherein the QR code generator is located at the secured server remote from the drug monitoring tool.
5. The drug monitoring tool of claim 1 , further comprising an activation toolkit that allows the drug monitoring tool to provide the graphical representation predictive of the time-varying therapeutic plasma protein level only after receiving the patient PK profile and a log of a first prophylactic infusion.
6. The drug monitoring tool of claim 1 , wherein the interactive user interface includes a graphical control element configured to receive patient input corresponding to a request for the time-varying therapeutic plasma protein level within the patient at a particular time selected by the patient; and wherein the interactive user interface is configured to display the graphical representation of the time-varying therapeutic plasma protein level within the patient at the particular time.
7. The drug monitoring tool of claim 6 , wherein the graphical control element is slidable between the plurality of zones.
8. The drug monitoring tool of claim 1 , wherein the graphical representation provides an estimated amount of time until the time-varying therapeutic plasma protein level reaches the danger zone.
9. A drug monitoring system, the system comprising: a remote server system comprising:
a Bayesian model of pharmacokinetic (PK) profiles of sampled patients, the Bayesian model including (i) a therapeutic plasma protein clearance and (ii) a volume of distribution relationship for a therapeutic plasma protein based upon at least one of patient age or body weight,
a PK server that determines a patient PK profile based upon the Bayesian model and at least one of a bodyweight, von Willebrand factor level, and an age of a patient, and a quick response (QR) code generator that generates a QR code storing the patient PK profile; and
a drug monitoring tool comprising:
a camera that reads the QR code,
a code processor that extracts the patient PK profile from the QR code, and
an interactive user interface that displays a graphical representation of a time-varying therapeutic plasma protein level of the patient determined by the drug monitoring system based on the timing and amount of an administered dose of a clotting factor VIII to the patient and the patient PK profile, the graphical representation delineating a plurality of zones within the graphical representation associated with the time-varying therapeutic plasma protein level, the plurality of zones comprising at least:
a safe zone indicating to the patient that the time-varying therapeutic plasma protein level is within a first concentration range considered safe for physical activity; and
a danger zone indicating to the patient that the time-varying therapeutic plasma protein level is within a second concentration range and physical activity should be limited.
10. The system of claim 9 , wherein the quick response (QR) code generator generates the QR code using a plurality of fields each independently selected from the group consisting: schema version, clinic patient ID, weight, alpha, beta, K21, V1, duration, dosing interval, FVIII baseline, target, trough, time above, time below, and timestamp.
11. The system of claim 9 , wherein the quick response (QR) code generator generates the QR code using a plurality of fields, each field encoded using UTF8.
12. The system of claim 9 , wherein the graphical representation provides an estimated amount of time until the time-varying therapeutic plasma protein level reaches the danger zone.
13. A method of using a patient pharmacokinetic (PK) profile to predict drug levels, the method comprising:
receiving, at a user device, a patient PK profile for a clotting factor from a server system that determines the patient PK profile based on a Bayesian model of sampled patients and at least one of a bodyweight, a von Willebrand factor level, and an age of a patient;
determining, by the user device, time-varying levels of the clotting factor predicted using the patient PK profile to result in the patient from the timing and amount of an administered dose of the clotting factor; and
displaying, via an interactive user interface of the user device, the time-varying levels of the clotting factor predicted in the patient within a plurality of zones, the time-varying levels of the clotting factor being positioned within either:
a safe zone indicating to the patient that the time-varying levels of the clotting factor is within a first concentration considered safe for physical activity; or
a danger zone indicating to the patient that the time-varying levels of the clotting factor is within a second concentration and physical activity should be limited.
14. The method of claim 13 , further comprising:
providing a graphical control element by which a user can inquire about the time-varying levels of the clotting factor at a particular time selected by the user; and
displaying a first estimated level of the clotting factor predicted using the patient PK profile to be in the patient at the particular time.
15. The method of claim 14 , wherein the graphical control element is slidable between the plurality of zones.
16. The method of claim 13 , wherein the Bayesian model comprises (i) a clotting factor clearance and (ii) a volume of distribution relationship for the clotting factor based on age or bodyweight of the sampled patients.
17. The method of claim 13 , wherein:
receiving the patient PK profile includes using the user device for:
scanning a quick response (QR) code storing patient information that includes at least PK profile information; and
extracting and processing the patient information stored within the QR code.
18. The method of claim 17 , wherein the server system generates the QR code having patient information encrypted using AES-256 encryption with cipher block chaining (CBC) and public-key cryptography standards (PKCS) padding.
19. The method of claim 17 , wherein the QR code includes at least one of or any combination of: patient identifying information, patient physiological data, patient dosing information, and/or PK profile information of the patient, wherein the patient dosing information includes a prophylactic dosing regimen for a particular clotting factor VIII drug.
20. The method of claim 13 , further comprising performing, for the patient, the determining step and the displaying step in response to receiving the patient PK profile and a log of a first prophylactic infusion.